Abstract
Specific immunotherapy with once-daily grass allergen tablet 75,000 SQ-T (2,800 BAU)(Grazax® Phleum pratense, ALK-Abelló A/S) is efficacious and well-tolerated in adult rhinoconjunctivitis patients. Recently, the tolerability of Grazax has also been demonstrated in Phase I trials in children. The present phase III study investigated both the efficacy and safety in children.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
